Skip to content
OpenCapital
Get started

Marker Therapeutics, Inc. MRKR Q4 2025 Annual earnings

Reported March 18, 2026 · Before market open

Revenue$1.1MBeat by $417.9K
EPS-$0.04Beat by $0.17
Revenue estimate$682.1K
EPS estimate-$0.21

Next report

Aug 13, 2026 (In 2 weeks)
Revenue estimate$682.1K
EPS estimate-$0.25

Versus estimates

Revenue

Q4 2025$1.1MBeat by $417.9K
Q3 2025$1.2MBeat by $509.9KQ2 2025$861.2KBeat by $430.6KQ1 2025$349.1KBeat by $174.6KQ4 2024$2.3MBeat by $1.0M

Diluted EPS

Q1 2026-$0.16Beat by $0.02
Q4 2025-$0.04Beat by $0.17
Q3 2025-$0.12Beat by $0.24Q2 2025-$0.29Beat by $0.01Q1 2025-$0.27Beat by $0.39Q4 2024-$0.42Miss by $0.20

Ask the moment Marker Therapeutics, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Marker Therapeutics, Inc. report Q4 2025 earnings?
Marker Therapeutics, Inc. (MRKR) reported Q4 2025 earnings on March 18, 2026 before market open.
What were Marker Therapeutics, Inc.'s Q4 2025 revenue and EPS?
Marker Therapeutics, Inc. reported revenue of $1.1M and eps of $-0.04 for Q4 2025.
Did Marker Therapeutics, Inc. beat estimates in Q4 2025?
Revenue beat the consensus estimate of $682.1K by $417.9K. EPS beat the consensus estimate of $-0.21 by $0.17.
How did Marker Therapeutics, Inc.'s Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 51.1% from $2.3M a year earlier and eps grew 90.5% from $-0.42.
Where can I find Marker Therapeutics, Inc.'s Q4 2025 SEC filings?
You can read the 8-K earnings release (0001104659-26-031309) and the 10-K periodic report (0001104659-26-031274) directly on SEC EDGAR. The filing index links above go to sec.gov.